Floatz logo

Autologous Chimeric Antigen Receptor T Cell Transfusing Agent Targeting Cd22

Plasma Cell Neoplasm

PersonGen BioTherapeutics (Suzhou) Co., Ltd.Cell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

21 Active assets in the Plasma Cell Neoplasm cohort.

Asset / SponsorPhaseRating
cc-5013
Hellenic Society of Hematology
Phase 3BBB
DEXAMETHASONE
Hellenic Society of Hematology
Phase 3BBB
Cyclophosphamide
Affiliated Hospital to Academy of Military Medical Sciences
Phase 3BB
Fludarabine
Affiliated Hospital to Academy of Military Medical Sciences
Phase 3BB
Fludarabine
Affiliated Hospital to Academy of Military Medical Sciences
Phase 3BB

View all 50 →

Same molecule, other indications

Autologous Chimeric Antigen Receptor T Cell Transfusing Agent Targeting Cd22 is also rated in:

primary cutaneous follicle center lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
MALT lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →